Richard Staines, Author at

HealthwareInternational_PaoloGuglielmoni

Digital health consulting, marketing communications group Healthware has appointed Paolo Guglielmoni as its new head of experience. He

Healthware appoints Paolo Guglielmoni as head of experience

https://pharmaphorum.com/news/healthware-paolo-guglielmoni-head-experience/

Market Access/ News/ News

Japan approves two more COVID vaccines as fourth infection wave hits

Richard Staines coronavirus, COVID-19, infectious diseases, vaccine 0 Comment

Japan has approved two more coronavirus vaccines, while expanding a state of emergency to cover the southern island

Japan approves two more COVID vaccines as fourth infection wave hits

https://pharmaphorum.com/news/japan-approves-two-more-covid-vaccines-as-fourth-infection-wave-hits/

R&D/ Views & Analysis/ Views and analysis

Arecor heads for London Stock Exchange with drug reformulation strategy

Richard Staines AIM, Arecor, biologics, IPO 0 Comment

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its

Arecor heads for London Stock Exchange with drug reformulation strategy

https://pharmaphorum.com/views-and-analysis/arecor-heads-for-london-stock-exchange-with-drug-reformulation-strategy/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

Richard Staines Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology 0 Comment

In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

https://pharmaphorum.com/news/allogene-announces-pivotal-trial/

News/ News/ R&D

Under-pressure GSK sells stake in respiratory diseases partner Innoviva

Richard Staines Elliott Management, GlaxoSmithKline, Innoviva, M&A 0 Comment

GlaxoSmithKline has sold its entire stake in its respiratory partner Innoviva, raising $392 million and simplifying its business

Under-pressure GSK sells stake in respiratory diseases partner Innoviva

https://pharmaphorum.com/news/gsk-sells-stake-in-respiratory-diseases-partner-innoviva/

News/ News/ Sales and Marketing

Avenir opens office in London’s Bankside

Richard Staines Avenir Global, Axon, Cherry, comms, Hanover, Medano 0 Comment

Avenir Global is bringing together all its healthcare brands in a new state-of-the-art office at Riverside House in

Avenir opens office in London’s Bankside

https://pharmaphorum.com/news/avenir-opens-office-in-londons-bankside/

Market Access/ News/ News

NICE rejects J&J’s prostate cancer drug Erleada in initial guidance

Richard Staines Johnson & Johnson, market access, NICE, Prostate cancer 0 Comment

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone

NICE rejects J&J’s prostate cancer drug Erleada in initial guidance

https://pharmaphorum.com/news/nice-rejects-jjs-prostate-cancer-drug-erleada-in-initial-guidance/

News/ News/ Oncology

LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies

Richard Staines Bristol-Myers Squibb, cancer, Merck & Co, metastatic melanoma 0 Comment

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this

LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies

https://pharmaphorum.com/news/bms-lag3-combination-outperforms-opdivo-in-advanced-melanoma-trial/

News/ News/ Oncology

Numab raises $110m to develop cancer bispecific antibodies

Richard Staines cancer, Novo Holdings, Numab 0 Comment

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to

Numab raises $110m to develop cancer bispecific antibodies

https://pharmaphorum.com/news/numab-raises-110m-to-develop-cancer-bispecific-antibodies/

Trending

About Richard Staines

Posts by Richard Staines:

Healthware appoints Paolo Guglielmoni as head of experience

Japan approves two more COVID vaccines as fourth infection wave hits

Arecor heads for London Stock Exchange with drug reformulation strategy

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

Under-pressure GSK sells stake in respiratory diseases partner Innoviva

Avenir opens office in London’s Bankside

NICE rejects J&J’s prostate cancer drug Erleada in initial guidance

LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies

Numab raises $110m to develop cancer bispecific antibodies

Trending

About Richard Staines

Posts by Richard Staines:

Login